A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination with Carboplatin in Patients with Advanced HER-2 Negative Breast Cancer

Trial Identifier: D081EC00001
Sponsor: AstraZeneca
NCTID:: NCT02561832
Start Date: November 2015
Primary Completion Date: September 2016
Study Completion Date: February 2017
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Spain Barcelona, Spain, 08035
Spain Madrid, Spain, 28034
Spain Madrid, Spain, 28050
Spain Valencia, Spain, 46010
Spain Zaragoza, Spain, 50009
United States of America, NY New York, NY, United States of America, 10065
United States of America, NY Stony Brook, NY, United States of America, 11794